- Home
- XGN
XGN
Exagen Inc.
as 07-26-2024 4:00pm EST
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | VISTA |
| Market Cap: | 33.9M | IPO Year: | 2019 |
| Target Price: | $7.00 | AVG Volume (30 days): | 26.1K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.09 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.30 - $2.95 | Next Earning Date: | 08-05-2024 |
| Revenue: | $55,733,000 | Revenue Growth: | 20.12% |
| Revenue Growth (this year): | 7.16% | Revenue Growth (next year): | 16.16% |
Stock Insider Trading Activity of Exagen Inc. (XGN)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ABALLI JOHN | XGN | President and CEO | May 16 '24 | Buy | $1.92 | 40,401 | $77,569.92 | 40,401 | SEC Form 4 |
| Adawi Kamal | XGN | CFO and Corporate Secretary | Mar 4 '24 | Sell | $1.91 | 9,297 | $17,747.04 | 247,236 | SEC Form 4 |
| Adawi Kamal | XGN | CFO and Corporate Secretary | Mar 4 '24 | Sell | $1.91 | 3,487 | $6,659.82 | 243,749 | SEC Form 4 |
| Adawi Kamal | XGN | CFO and Corporate Secretary | Feb 6 '24 | Sell | $1.95 | 6,738 | $13,133.04 | 181,533 | SEC Form 4 |
Latest Exagen Inc. News
XGN Breaking Stock News: Dive into XGN Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
Exagen to Announce Second Quarter 2024 Results on August 5, 2024
Zacks
a month ago
Why Fast-paced Mover Exagen (XGN) Is a Great Choice for Value Investors
GuruFocus.com
2 months ago
Exagen Inc (XGN) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and Margin ...
Simply Wall St.
2 months ago
Exagen First Quarter 2024 Earnings: Beats Expectations
Zacks
2 months ago
Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates
GlobeNewswire
2 months ago
Exagen Inc. Reports Strong First Quarter 2024 Results: Raises Guidance for Full Year
GlobeNewswire
3 months ago
Exagen Announces Campaign for Lupus Awareness Month
GlobeNewswire
3 months ago
Exagen to Announce First Quarter 2024 Results on May 13, 2024
Compare XGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "XGN Exagen Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.